Skip to main content
. Author manuscript; available in PMC: 2014 Jul 14.
Published in final edited form as: Sci Transl Med. 2011 Jul 20;3(92):92ra64. doi: 10.1126/scitranslmed.3002097

Figure 6. AAV9-S100A1 gene therapy restores high energy phosphate and dinucleotide content in failing myocardium.

Figure 6

(A and B) Assessment of the bioenergetic marker CP/ATP (A) and NADH/NAD (B) revealed significantly decreased values in HF control groups compared to sham. AAV9-S100A1 gene therapy restores CP/ATP and NADH/NAD ratios to normal, indicative of reconstituted energy homeostasis and redox-state in failing hearts (n=6 different animals in each group, each measurement was carried out in triplicate). †P<0.05 sham vs. HF-saline and HF-Luc, *P<0.05 HF-S100A1 vs. HF-saline and HF-Luc. Data are presented as mean±SEM.